A detailed history of New Edge Advisors, LLC transactions in Novo Cure LTD stock. As of the latest transaction made, New Edge Advisors, LLC holds 130 shares of NVCR stock, worth $2,605. This represents 0.0% of its overall portfolio holdings.

Number of Shares
130
Previous 130 -0.0%
Holding current value
$2,605
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

SELL
$56.44 - $118.81 $6,490 - $13,663
-115 Reduced 46.94%
130 $7,000
Q4 2022

Feb 14, 2023

BUY
$63.98 - $85.37 $15,675 - $20,915
245 New
245 $17,000
Q4 2020

Jan 27, 2021

SELL
$112.16 - $174.14 $414,879 - $644,143
-3,699 Closed
0 $0
Q3 2020

Nov 03, 2020

BUY
$58.05 - $111.31 $214,726 - $411,735
3,699 New
3,699 $412,000
Q2 2020

Jul 29, 2020

SELL
$57.2 - $74.41 $177,777 - $231,266
-3,108 Closed
0 $0
Q1 2020

May 04, 2020

BUY
$57.05 - $95.75 $177,311 - $297,591
3,108 New
3,108 $209,000

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $2.1B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.